52 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Article Searches
Labcorp (LH) Presents New Research on Precision Diagnostics https://www.zacks.com/stock/news/2242254/labcorp-lh-presents-new-research-on-precision-diagnostics?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2242254 Mar 18, 2024 - Labcorp's (LH) new research shows how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer.
Charles River (CRL) Extends Gene Therapy Offering With New Pact https://www.zacks.com/stock/news/2241549/charles-river-crl-extends-gene-therapy-offering-with-new-pact?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2241549 Mar 15, 2024 - Charles River's (CRL) partnership with Navega Therapeutics will enable it to leverage its strong AAV portfolio and leading gene therapy CDMO capabilities.
Inspira Technologies (IINN) Releases Favorable Data on VORTX https://www.zacks.com/stock/news/2240756/inspira-technologies-iinn-releases-favorable-data-on-vortx?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240756 Mar 14, 2024 - Inspira Technologies' (IINN) proprietary orbiting oxygenation technology eliminates the need for membrane fibers, thereby reducing pressure differentials and high shear stress.
Here's Why You Should Retain Charles River (CRL) Stock Now https://www.zacks.com/stock/news/2240683/here-s-why-you-should-retain-charles-river-crl-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2240683 Mar 14, 2024 - Investors remain optimistic about Charles River (CRL) due to the strength of the RMS segment.
Here's Why You Should Retain Globus Medical (GMED) Stock Now https://www.zacks.com/stock/news/2240217/here-s-why-you-should-retain-globus-medical-gmed-stock-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2240217 Mar 13, 2024 - Investors are optimistic about Globus Medical (GMED), led by growth in the U.S. spine business and progress in the recently merged NuVasive business.
Integra LifeSciences (IART) Introduces MicroMatrix Flex https://www.zacks.com/stock/news/2239482/integra-lifesciences-iart-introduces-micromatrix-flex?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2239482 Mar 12, 2024 - Integra LifeSciences' (IART) MicroMatrix Flex has a flexible tip that delivers a flowable version of the Urinary Bladder Matrix (UBM) technology.
Thermo Fisher (TMO) Unveils CorEvitas Clinical Registry in GPP https://www.zacks.com/stock/news/2238707/thermo-fisher-tmo-unveils-corevitas-clinical-registry-in-gpp?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2238707 Mar 11, 2024 - Thermo Fisher's (TMO) new CorEvitas clinical registry addresses an unmet need for real-world evidence related to the clinical and patient-reported outcomes of patients with GPP.
Here's Why You Should Retain Teleflex (TFX) Stock for Now https://www.zacks.com/stock/news/2238699/here-s-why-you-should-retain-teleflex-tfx-stock-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2238699 Mar 11, 2024 - Investors are optimistic about Teleflex (TFX) on robust growth in the Vascular business and strong Urolift prospects.
Medtronic's (MDT) MiniMed 780G System Study Data Favorable https://www.zacks.com/stock/news/2238698/medtronic-s-mdt-minimed-780g-system-study-data-favorable?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2238698 Mar 11, 2024 - Medtronic's (MDT) data from a recent study indicate that the MiniMed 780G system exceeds international targets for TIR and even brings patients closer to euglycemia.
Here's Why You Should Retain Walgreens Boots (WBA) For Now https://www.zacks.com/stock/news/2237551/here-s-why-you-should-retain-walgreens-boots-wba-for-now?cid=CS-ZC-FT-analyst_blog|rank_focused-2237551 Mar 07, 2024 - Investors are optimistic about Walgreens Boots (WBA), led by its strategic partnerships and long-term growth model.

Pages: 123456

<Page 2>